SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Cue Health
("Cue") (Nasdaq: HLTH), a healthcare technology company, today
announced that its direct-to-consumer (DTC) virtual health platform
will launch on November 15th, making
Cue's first-of-its-kind molecular COVID-19 test available to people
across the United States through
Cue's new eCommerce site and in-app shop. Individual consumers will
now be able to harness the power of Cue's COVID-19 test, which is
already trusted and used by world-class organizations like Google,
Mayo Clinic, the NBA, and MLB, among others. Earlier this year, the
Cue COVID-19 Test for Home and Over The Counter (OTC) Use was the
first molecular test to receive FDA authorization for at-home use
without a prescription. Beyond COVID-19 testing needs, Cue's new
membership offering – Cue+™– will offer members 24/7 on-demand
access to board certified physicians, e-prescription services,
CDC-compliant test results for travel through in-app video
proctoring, and same-day delivery of Cue products in a number of
major markets.
"Cue Health to launch DTC virtual health platform featuring its
COVID-19 self-test trusted by Google, Mayo Clinic, the NBA, and
MLB"
Cue simplifies the COVID-19 testing process by combining the
speed of rapid antigen tests with the lab-quality accuracy of PCR
tests. Cue's portable COVID-19 test showed 97.8% concordance with
central lab PCR tests, as verified in an independent study
conducted by Mayo Clinic1. Authorized by the
FDA to test both symptomatic and asymptomatic adults and children
ages two and up using a lower nasal swab, Cue's COVID-19 test
delivers a comfortable and stress-free testing experience. Test
results are delivered to the user's smart mobile device in just 20
minutes.
"We've had a lot of interest from the general public eager to
purchase our COVID-19 tests: from parents who need to keep their
kids healthy in school to international business travelers to
families who want to gather safely this holiday season. We're
excited to make Cue available to a broader audience next week to
deliver fast and accurate COVID-19 testing at home or on the go,"
said Clint Sever, Cue's Co-Founder
and Chief Product Officer.
Cue+ membership not only meets people's at-home testing needs
but also enables them to share Cue test results and discuss other
health issues with a doctor on-demand within the new Cue Health
App. The Cue platform is integrated with last-mile delivery
services so members can get products at home when they need them
the most. And as the anticipated COVID-19 antivirals requiring
time-sensitive administration come to market, Cue expects to be
able to enable consumers to go from test result to physician
consultation to antiviral treatment, when appropriate, within the
comfort and convenience of their own homes.
"We're pleased to be able to offer consumers our best-in-class
COVID-19 tests as part of Cue's integrated care platform, which we
believe can help empower individuals and families to live their
healthiest lives," said Ayub
Khattak, Co-Founder and CEO of Cue. "With Cue+ membership
and our new Cue Health App, we aim to make the healthcare journey —
from testing to diagnosis to treatment — more accessible, more
convenient, and more timely."
The Cue experience starts with the Cue Reader ($249), a reusable and compact device that
processes each test and connects wirelessly with a user's mobile
device to deliver results in 20 minutes via the Cue Health
App (for both iOS and Android). The Cue Reader is compatible
with Cue's COVID-19 Test Cartridge ($225/3-pack) and other tests that are in
development. Cue's COVID-19 tests are self-contained, single-use
cartridges that make testing simple and convenient. These products
will be bundled together for discounts and available for purchase
as part of two new Cue+ Membership packages
when shop.cuehealth.com launches on November 15th.
Cue+ Membership features:
- Cue+ Essential™($49.99/month): lab-quality, at-home testing
and convenient, easy-to-use Cue Virtual Care to meet your needs
whenever, wherever. Ten COVID-19 tests per year, 20% off additional
COVID-19 tests, and free same-day delivery in select markets.
Discounted price on the Cue Reader (sold separately).
- Cue+ Complete™($89.99/month): all the benefits of Cue+
Essential, plus CDC-compliant, supervised COVID-19 testing for
travel, work, or school. Even more COVID-19 tests (20 per year) and
front-of-the-line access to Cue's future care offerings.
Cue's Virtual Care capabilities will include:
- CDC-compliant test results through in-app video proctoring for
travel, work, and school (for Cue+ Complete members)
- 24/7 access to chat with board-certified physicians
- New e-prescriptions and prescription renewals
- Physician-ordered lab tests
Cue aims to provide individuals with the ability to proactively
monitor and manage their health, with actionable information that
they can share with healthcare providers in real-time. Cue's
planned future care offerings – all of which are intended to be
compatible with the Cue Reader – include products and services
across the categories of respiratory health (such as for influenza,
RSV, and strep throat), sexual health (such as for chlamydia and
gonorrhea), cardiac and metabolic health (such as for cholesterol
and HbA1c), women's and men's health, and chronic disease
management.
For more information about Cue's products and services available
on November 15th, please visit
cuehealth.com.
Please download press assets to accompany today's announcement
here.
About Cue Health
Cue Health (Nasdaq: HLTH) is a
healthcare technology company that puts consumers in control of
their health information and places diagnostic information at the
center of care. Cue Health enables people to manage their health
through real-time, actionable, and connected health information,
offering individuals and their healthcare providers easy access to
lab-quality diagnostics anywhere, anytime, in a device that fits in
the palm of the hand. Cue Health's first-of-its-kind COVID-19 test
was the first FDA-authorized molecular diagnostic test for at-home
and over-the-counter use without a prescription and physician
supervision. Outside the United
States, Cue Health has received the CE mark in the European
Union, Interim Order authorization from Health Canada, and
regulatory approval from India's
Central Drugs Standard Control Organisation. Cue was founded in
2010 and is headquartered in San
Diego. For more information, please visit
www.cuehealth.com.
Forward-Looking Statements
Statements in this press
release about future expectations, plans and prospects, as well as
any other statements regarding matters that are not historical
facts, may constitute "forward-looking statements". The words,
without limitation, "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these or similar identifying words. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including the factors
discussed in the "Risk Factors" section of the prospectus dated
September 23, 2021 filed by Cue with
the SEC. Any forward-looking statements contained in this press
release are based on the current expectations of Cue's management
team and speak only as of the date hereof, and Cue specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
The Cue COVID-19 Test for Home and Over The Counter (OTC) Use
and the Cue COVID-19 Test (for professional use) have not been FDA
cleared or approved; but have been authorized by FDA under an
Emergency Use Authorization (EUA). These products have been
authorized only for the detection of nucleic acid from SARS-CoV-2,
not for any other viruses or pathogens. The emergency use of these
products is only authorized for the duration of the declaration
that circumstances exist justifying the authorization of emergency
use of in vitro diagnostics for detection and/or diagnosis of
COVID-19 under Section 564(b)(1) of the Federal Food, Drug and
Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is
terminated or authorization is revoked sooner.
1 In an independent study
conducted by Mayo Clinic Laboratories, the overall concordance
between Cue's point-of-care test and the reference laboratory tests
was found to be 97.8%. Details on the study can be found
here.
View original
content:https://www.prnewswire.com/news-releases/cue-health-to-launch-direct-to-consumer-virtual-health-platform-featuring-its-covid-19-self-test-trusted-by-google-mayo-clinic-the-nba-and-mlb-301419256.html
SOURCE Cue Health Inc.